Lecanemab, an Alzheimer’s drug from Eisai and Biogen, was found to slow the cognitive decline among people with early signs of the disease.
Author: Ken Alltucker, USA TODAY
Here’s why private Medicare plans are set to pass traditional Medicare enrollment
More than 28 million older adults enrolled in Medicare plans administered by private insurance companies rather than the federal government.
‘Calm before the storm’: Health insurance costs set to spike after they stayed mostly flat in 2022, survey finds
Kaiser Family Foundation survey reports average cost for an employer-provided health increased just 1% this year.
Biden administration vows tougher oversight of poor-performing nursing homes with safety issues
The Biden administration will bolster oversight of poor-performing nursing homes with escalating fines and terminating federal funding.
More than 1.3M Americans ration life-saving insulin due to cost. That’s ‘very worrisome’ to doctors.
Doctors warn the high cost of insulin puts all type 1 and some type 2 diabetes patients at risk of medical complications, hospitalization and death.
Inflation is near a four-decade high. So why aren’t health care costs significantly higher?
For the first time in 40 years, inflation is rising faster than medical costs. But employers and health insurers are bracing for that to soon change.
Survey: More than 2.5 million middle and high school students still vape, despite crackdowns
The 2022 National Youth Tobacco Survey showed 14.1% of high school students and 3.3% of middle school students vaped at least once over past 30 days.
Alzheimer’s drug slowed progression of disease in late-stage study, drugmakers say
Officials said they will submit the new trial results to the FDA to bolster its case that lecanemab should be approved as an Alzheimer’s treatment.
HIV groups struggle to get insurance coverage for expensive prevention drugs, lab tests
HIV activists say people who are eligible for free HIV prevention care often don’t get full coverage even though federal law says they should.
‘Guardrails’ needed? Telehealth fraud cost Medicare $128M in first year of COVID pandemic, feds say
Improper claims from doctors and telehealth providers cost Medicare $128M in the first year of the COVID pandemic, according to a new federal report.